Clinical and immunomodulating effects of ketamine in horses with experimental endotoxemia

Journal of Veterinary Internal Medicine

Volumn 25, Issue 4, 2011, Pages 934-943

  Alcott, C J ^a   Sponseller, B A ^a   Wong, D M ^a   Davis, J L ^c   Soliman, A M ^a   Wang, C ^a,b   Hsu, W ^a  

^a IOWA STATE UNIVERSITY   (United States)

^b Iowa State University   (United States)

^c NORTH CAROLINA STATE UNIVERSITY   (United States)

Author keywords

Horses; Immunomodulation; Lipopolysaccharide; Subanesthetic ketamine; Thromboxane; Tumor necrosis factor

Indexed keywords

IMMUNOLOGIC FACTOR; KETAMINE; LIPOPOLYSACCHARIDE; THROMBOXANE B2; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL; ANIMAL DISEASE; AREA UNDER THE CURVE; ARTICLE; BLOOD; BODY TEMPERATURE; BREATHING; DRUG EFFECT; ENDOTOXEMIA; FEMALE; HEART RATE; HORSE; HORSE DISEASE; IMMUNOLOGY; NONPARAMETRIC TEST; RANDOMIZATION;

ANIMALS; AREA UNDER CURVE; BODY TEMPERATURE; ENDOTOXEMIA; FEMALE; HEART RATE; HORSE DISEASES; HORSES; IMMUNOLOGIC FACTORS; KETAMINE; LIPOPOLYSACCHARIDES; RANDOM ALLOCATION; RESPIRATION; STATISTICS, NONPARAMETRIC; THROMBOXANE B2; TUMOR NECROSIS FACTOR-ALPHA;

ANIMALIA; CANIS FAMILIARIS; EQUIDAE; ESCHERICHIA COLI; RODENTIA;

EID: 79960560531     PISSN: 08916640     EISSN: 19391676     Source Type: Journal    
DOI: 10.1111/j.1939-1676.2011.0749.x     Document Type: Article

References (40)

1. Werners AH, Bull S, Fink-Gremmels J. Endotoxaemia: A review with implications for the horse. Equine Vet J 2005;37:371-383.
2. Chaffin MK, Carter GK, Byars TD. Equine bacterial pleuropneumonia: Treatment, sequelae, and prognosis. Compend Contin Educ Pract Vet 1994;16:1585-1596.
3. Parsons CS, Orsini JA, Krafty R, et al. Risk factors for development of acute laminitis in horses during hospitalization: 73 cases (1997-2004). J Am Vet Med Assoc 2007;230:885-889.
4. Mannel DN, Echtenacher B. TNF in the Inflammatory Response. Cd14 in the Inflammatory Response. Basel: Karger; 2000:141-161.
5. Menzies-Gow NJ, Sepulveda MF, Bailey SR, et al. Roles of thromboxane A(2) and 5-hydroxytryptamine in endotoxin-induced digital vasoconstriction in horses. Am J Vet Res 2008;69:199-207.
6. Morris DD, Moore JN. Endotoxin-induced production of thromboxane and prostacyclin by equine peritoneal-macrophages. Circ Shock 1987;23:295-303.
7. Brooks AC, Menzies-Gow NJ, Wheeler-Jones C, et al. Endotoxin-induced activation of equine platelets: Evidence for direct activation of p38 MAPK pathways and vasoactive mediator production. Inflamm Res 2007;56:154-161.
8. Alcott C, Wong D, Brockus C, et al. Hemostasis. Compend Equine: Cont Educ Vet 2009;4:78-87.
9. Cook VL, Shults JJ, McDowell MR, et al. Anti-inflammatory effects of intravenously administered lidocaine hydrochloride on ischemia-injured jejunum in horses. Am J Vet Res 2009;70:1259-1268.
10. Bryant CE, Ouellette A, Lohmann K, et al. The cellular Toll-like receptor 4 antagonist E5531 can act as an agonist in horse whole blood. Vet Immunol Immunopathol 2007;116:182-189.
11. Braim AEP, MacDonald MH, Bruss ML, et al. Effects of intravenous administration of pirfenidone on horses with experimentally induced endotoxemia. Am J Vet Res 2009;70:1031-1042.
12. Moore JN, Norton N, Barton MH, et al. Rapid infusion of a phospholipid emulsion attenuates the effects of endotoxaemia in horses. Equine Vet J 2007;39:243-248.
13. Barton MH, Moore JN, Norton N. Effects of pentoxifylline infusion on response of horses to in vivo challenge exposure with endotoxin. Am J Vet Res 1997;58:1300-1307.
14. Barton MH, Parviainen A, Norton N. Polymyxin B protects horses against induced endotoxaemia in vivo. Equine Vet J 2004;36:397-401.
15. Taniguchi T, Shibata K, Yamamoto K. Ketamine inhibits endotoxin-induced shock in rats. Anesthesiology 2001;95:928-932.
16. Taniguchi T, Takemoto Y, Kanakura H, et al. The dose-related effects of ketamine on mortality and cytokine responses to endotoxin-induced shock in rats. Anesth Analg 2003;97:1769-1772.
17. Sun J, Wang XD, Liu H, et al. Ketamine suppresses endotoxin-induced NF-kappa B activation and cytokines production in the intestine. Acta Anaesthesiolog Scand 2004;48:317-321.
18. Sun J, Zhou ZQ, Lv R, et al. Ketamine inhibits LPS-induced calcium elevation and NF-kappa B activation in monocytes. Inflamm Res 2004;53:304-308.
19. Lankveld DPK, Bull S, Van Dijk P, et al. Ketamine inhibits LPS-induced tumour necrosis factor-alpha and interleukin-6 in an equine macrophage cell line. Vet Res 2005;36:257-262.
20. Hirakata H, Nakagawa T, Nakamura K, et al. Ketamine inhibits platelet aggregation by suppressed calcium mobilization. Anesthesiology 1999;91:A438.
21. Helmer KS, Cui Y, Chang L, et al. Effects of ketamine/xylazine on expression of tumor necrosis factor-alpha, inducible nitric oxide synthase, and cyclo-oxygenase-2 in rat gastric mucosa during endotoxemia. Shock 2003;20:63-69.
22. DeClue AE, Lechner ES, Dodam JR, et al. Effects of ketamine infusion on hemodynamic and immunologic variables in a canine model of endotoxemia. J Vet Inter Med 2006;20:757-757.
23. DeClue AE, Cohn LA, Lechner ES, et al. Effects of subanesthetic doses of ketamine on hemodynamic and immunologic variables in dogs with experimentally induced endotoxemia. Am J Vet Res 2008;69:228-232.
24. Lankveld DPK, Driessen B, Soma LR, et al. Pharmacodynamic effects and pharmacokinetic profile of a long-term continuous rate infusion of racemic ketamine in healthy conscious horses. J Vet Pharmacol Therapeut 2006;29:477-488.
25. Toribio RE, Kohn CW, Hardy J, et al. Alterations in serum parathyroid hormone and electrolyte concentrations and urinary excretion of electrolytes in horses with induced endotoxemia. J Vet Inter Med 2005;19:223-231.
26. Weigand MA, Schmidt H, Zhao QY, et al. Ketamine modulates the stimulated adhesion molecule expression on human neutrophils in vitro. Anesth Analg 2000;90:206-212.
27. Suliburk JW, Helmer KS, Gonzalez EA, et al. Ketamine attenuates liver injury attributed to endotoxemia: Role of cyclooxygenase-2. Surgery 2005;138:134-140.
28. Waterman AE, Robertson SA, Lane JG. Pharmacokinetics of intravenously administered ketamine in the horse. Res Vet Sci 1987;42:162-166.
29. Kaka JS, Klavano PA, Hayton WL. Pharmacokinetics of ketamine in the horse. Am J Vet Res 1979;40:978-981.
30. Tranquilli WJ, Thurmon JC, Grimm KA, eds. Lumb and Jones' Veterinary Anesthesia and Analgesia, 4th ed. Ames, IA: Blackwell Publishing; 2007.
31. Fielding CL, Brumbaugh GW, Matthews NS, et al. Pharmacokinetics and clinical effects of a subanesthetic continuous rate infusion of ketamine in awake horses. Am J Vet Res 2006;67:1484-1490.
32. Larenza MP, Peterbauer C, Landoni MF, et al. Stereoselective pharmacokinetics of ketamine and norketamine after constant rate infusion of a subanesthetic dose of racemic ketamine or S-ketamine in Shetland ponies. Am J Vet Res 2009;70:831-839.
33. Schmidt H, Ebeling D, Bauer H, et al. Ketamine attenuates endotoxin-induced leukocyte adherence in rat mesenteric venules. Crit Care Med 1995;23:2008-2014.
34. Morris DD, Crowe N, Moore JN. Correlation of clinical and laboratory data with serum tumor-necrosis-factor activity in horses with experimentally induced endotoxemia. Am J Vet Res 1990;51:1935-1940.
35. Sun J, Li F, Chen J, et al. Effect of ketamine on NF-kappa B activity and TNF-alpha production in endotoxin-treated rats. Ann Clin Lab Sci 2004;34:181-186.
36. Taniguchi T, Kanakura H, Takemoto Y, et al. The antiinflammatory effects of ketamine in endotoxemic rats during moderate and mild hypothermia. Anesth Analg 2004;98:1114-1120.
37. Suliburk JW, Gonzalez EA, Moore-Olufemi SD, et al. Ketamine inhibits lipopolysacharide (LPS) induced gastric luminal fluid accumulation. J Surg Res 2005;127:203-207.
38. DeClue AE, Cohn LA, Hsu CC, et al. The effects of ketamine on LPS-induced lung injury in rats. Crit Care Med 2005;33:A145-A145.
39. Takenaka I, Ogata M, Koga K, et al. Ketamine suppresses endotoxin-induced tumor-necrosis-factor-alpha production in mice. Anesthesiology 1994;80:402-408.
40. Allen GK, CampbellBeggs C, Robinson JA, et al. Induction of early-phase endotoxin tolerance in horses. Equine Vet J 1996;28:269-274.